Trial Profile

A Phase 1a/1b Study of ELVN-001 for the Treatment of Chronic Myeloid Leukemia

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 08 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ELVN-001 (Primary)
Indications Chronic myeloid leukaemia
Focus Adverse reactions; First in man; Proof of concept
Acronyms CML; ENABLE
Sponsors Enliven Therapeutics

Most Recent Events

03 Jul 2025 Planned number of patients changed from 180 to 200.
13 Jun 2025 Result (n=53) presented in the Enliven Therapeutics Media Release
13 Jun 2025 According to an Enliven Therapeutics media release, company presented positive data from the Phase 1 ENABLE clinical trial in an oral presentation at the European Hematology Association (EHA) 2025 Congress taking place June 12-15 in Milan, Italy, and virtually.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com